REVIEW

Autoregulation of hepatic glucose production

Mary Courtney Moore, Cynthia C Connolly and Alan D Cherrington

702 Light Hall, Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, Tennessee 37232–0615 USA

(Correspondence should be addressed to M C Moore)

Abstract

In vitro evidence indicates that the liver responds directly to changes in circulating glucose concentrations with reciprocal changes in glucose production and that this autoregulation plays a role in maintenance of normoglycemia. Under in vivo conditions it is difficult to separate the effects of glucose on neural regulation mediated by the central nervous system from its direct effect on the liver. Nevertheless, it is clear that nonhormonal mechanisms can cause significant changes in net hepatic glucose balance. In response to hyperglycemia, net hepatic glucose output can be decreased by as much as 60–90% by nonhormonal mechanisms. Under conditions in which hepatic glycogen stores are high (i.e. the overnight-fasted state), a decrease in the glycogenolytic rate and an increase in the rate of glucose cycling within the liver appear to be the explanation for the decrease in hepatic glucose output seen in response to hyperglycemia. During more prolonged fasting, when glycogen levels are reduced, a decrease in gluconeogenesis may occur as a part of the nonhormonal response to hyperglycemia.

A substantial role for hepatic autoregulation in the response to insulin-induced hypoglycemia is most clearly evident in severe hypoglycemia (≤2.8 mmol/l). The nonhormonal response to hypoglycemia apparently involves enhancement of both gluconeogenesis and glycogenolysis and is capable of supplying enough glucose to meet at least half of the requirement of the brain. The nonhormonal response can include neural signaling, as well as autoregulation. However, even in the absence of the ability to secrete counterregulatory hormones (glucocorticoids, catecholamines, and glucagon), dogs with denervated livers (to interrupt neural pathways between the liver and brain) were able to respond to hypoglycemia with increases in net hepatic glucose output. Thus, even though the endocrine system provides the primary response to changes in glycemia, autoregulation plays an important adjunctive role.

Introduction

The liver plays a unique role in the regulation of carbohydrate metabolism because it is able both to take up and release glucose, thus helping to dampen variations in blood glucose. For at least 60 years evidence has existed which suggests that the liver is able to respond directly to changes in blood glucose with reciprocal changes in hepatic glucose output (1), a phenomenon known as hepatic autoregulation.

In vitro data provide strong support for the existence of autoregulation. The perfused rat liver increases its rate of glucose output when the perfusate contains no glucose or a low glucose concentration and decreases glucose output when the perfusate glucose concentration is high (2–5). In vivo studies in dogs, miniature pigs, and humans support the concept of hepatic autoregulation.

Autoregulation in response to hyperglycemia

In studies conducted in the 36 h fasted conscious dog, Shulman et al. (6, 7) noted that hyperglycemia (plasma glucose ~12 mmol/l for 2 h) brought about in the presence of basal concentrations of insulin and glucagon caused a fall in net hepatic glucose output of ~60%. Suppression of net hepatic glucose output occurred within 15 min of initiation of hyperglycemia, with maximal suppression being achieved within 30 min (6, 7). Net hepatic glucose output in control dogs, in which euglycemia was maintained, remained essentially unchanged (6, 7). Similarly, in the miniature pig, a gradual rise in plasma glucose from 4.0 to 8.5 mmol/l with insulin and glucagon maintained at basal concentrations resulted in suppression of tracer-determined endogenous glucose production (EndoRa) by 59% (8).
Hyperglycemia also inhibited glucose production in overnight-fasted humans. Saccá et al. (9) infused glucose continuously for 2 h in the presence of fixed pancreatic hormone concentrations. By 20 min, the plasma glucose concentration had risen from 4.2 to 5.5 mmol/l and EndoRa had declined plasma glucose concentration had risen from 4.2 to 5.5 mmol/l and EndoRa had declined. By 20 min, the plasma glucose concentration had risen from 4.2 to 5.5 mmol/l and EndoRa had declined. By 20 min, the plasma glucose concentration had risen from 4.2 to 5.5 mmol/l and EndoRa had declined. By 20 min, the plasma glucose concentration had risen from 4.2 to 5.5 mmol/l and EndoRa had declined. By 20 min, the plasma glucose concentration had risen from 4.2 to 5.5 mmol/l and EndoRa had declined. By 20 min, the plasma glucose concentration had risen from 4.2 to 5.5 mmol/l and EndoRa had declined. By 20 min, the plasma glucose concentration had risen from 4.2 to 5.5 mmol/l and EndoRa had declined. By 20 min, the plasma glucose concentration had risen from 4.2 to 5.5 mmol/l and EndoRa had declined. By 20 min, the plasma glucose concentration had risen from 4.2 to 5.5 mmol/l and EndoRa had declined. By 20 min, the plasma glucose concentration had risen from 4.2 to 5.5 mmol/l and EndoRa had declined. By 20 min, the plasma glucose concentration had risen from 4.2 to 5.5 mmol/l and EndoRa had declined. By 20 min, the plasma glucose concentration had risen from 4.2 to 5.5 mmol/l and EndoRa had declined. By 20 min, the plasma glucose concentration had risen from 4.2 to 5.5 mmol/l and EndoRa had declined. By 20 min, the plasma glucose concentration had risen from 4.2 to 5.5 mmol/l and EndoRa had declined. By 20 min, the plasma glucose concentration had risen from 4.2 to 5.5 mmol/l and EndoRa had declined. By 20 min, the plasma glucose concentration had risen from 4.2 to 5.5 mmol/l and EndoRa had declined. By 20 min, the plasma glucose concentration had risen from 4.2 to 5.5 mmol/l and EndoRa had declined. By 20 min, the plasma glucose concentration had risen from 4.2 to 5.5 mmol/l and EndoRa had declined.
apparently operates primarily through modulation in the rates of glycogenolysis and glucose cycling, rather than gluconeogenesis.

In 6h fasted rats infused for 2h with somatostatin and studied in the presence of basal insulin, basal glucagon, and ~2-fold basal plasma glucose, Rosetti et al. (20) observed that hepatic glucose production was decreased 58%. Glycogenolysis was almost completely inhibited, accounting for 89% of the decrease in hepatic glucose production. Gluconeogenesis was not significantly changed, and glucose cycling was increased by 2.5-fold when comparison was made with rats studied under euglycemic conditions (20).

Shiota et al. (21) examined rat livers perfused with basal insulin and glucagon, as well as glucose at a concentration of 5.8, 12.8, or 24.4 mmol/l. Net hepatic glucose output was inversely related to the perfusate glucose concentration, both in the presence of low glucagon concentrations (11 ng/l) and when the perfusate glucagon concentration was increased to 88 ng/l. There was no change in phosphorylase a activity with increasing perfusate glucose concentration; instead, the results were consistent with an increase in glucose cycling (21).

Petersen et al. (22) used $^{13}$C-nuclear magnetic resonance spectroscopy to assess rates of glycogenolysis in normal overnight-fasted humans during a 6h infusion of somatostatin and basal insulin. The plasma glucose concentrations were maintained at either 5 or 10 mmol/l. In comparison to the euglycemic subjects, the hyperglycemic individuals exhibited a 92% reduction in net hepatic glycogenolysis, primarily because of decreased flux through phosphorylase (22).

Studies in overnight-fasted conscious dogs (which have substantial stores of hepatic glycogen) confirmed the decrease in glycogenolysis in response to hyperglycemia (47). Dogs received somatostatin and basal amounts of intraportal glucagon and insulin while glucose was infused peripherally to increase the arterial glucose level ~2-fold in a gradual manner. Net hepatic glucose output ceased, and very slight net hepatic glucose uptake was evident (change in net hepatic glucose balance was 13 $\mu$mol/kg per min). The change in net hepatic glucose balance could be accounted for by the 78% reduction in net hepatic glycogenolysis, plus an 11-fold increase in hepatic glucose uptake. As in the studies of Rosetti et al. (20), gluconeogenesis was largely unaffected. Total net hepatic uptake of gluconeogenic precursors (a close but conservative estimate of the true gluconeogenic rate (47)) did not change significantly from baseline.

Normal humans overfed with carbohydrate for 5 days exhibited impairment of hepatic autoregulation (23). In spite of a 2.5-fold increase in plasma insulin concentrations, the 15 overfed subjects demonstrated significant increases (compared with their pre-overfeeding values) in plasma glucose and glucose $R_p$ after a 10h fast. These changes occurred in the overfed individuals despite a >50% increase in glucose cycling and a 42% decrease in the rate of gluconeogenesis ($P < 0.01$ vs pre-overfeeding for both changes). Thus these data suggest that a failure to suppress glycogenolysis was responsible for the increase in hepatic glucose output with overfeeding (23).

Even though it appears that changes in the rate of glycogenolysis play a primary role in the autoregulatory response of nondiabetic humans or animals when ample glycogen stores are present, evidence suggests that the liver is also capable of altering its rate of gluconeogenesis in response to changes in glycemia. In dogs studied after a 36h fast, when glycogen concentrations were approaching a stable minimum, hyperglycemia was sufficient to induce changes in gluconeogenesis (7). After 2h of hyperglycemia (12 mmol/l) in the presence of basal concentrations of insulin and glucagon, net hepatic fractional extraction of alanine had fallen by ~20%, and the conversion of $[^{14}$C]alanine and $[^{14}$C]lactate into glucose was reduced by ~60% (7). The decrease in the extraction of gluconeogenic precursors was not sufficient to account for all of the decrease in gluconeogenesis, implying an inhibitory effect of hyperglycemia on the hepatic gluconeogenic process (7).

Hellerstein et al. (24) also observed a decrease in the rate of gluconeogenesis in vivo in response to hyperglycemia. Those authors examined the response of 24h fasted rats to intravenous infusion of glucose at 83 or 166 $\mu$mol/kg per min for 4–8h (resultant plasma glucose concentrations not reported). Hepatic glucose production declined by 45–53% in response to glucose infusion, with an increase in glucose cycling accounting for more than half of the reduction in hepatic glucose production at the higher glucose infusion rate. Absolute rates of gluconeogenesis fell ~50% during both glucose infusions, with glucose recycling accounting for almost all of the gluconeogenic carbon utilized. Apparently hyperglycemia was able to suppress the uptake of gluconeogenic substrates by the liver (24).

**In vitro** data provide conflicting evidence in regard to the question of whether gluconeogenesis is suppressed in response to hyperglycemia. Using isolated rat hepatocytes, Sánchez-Gutiérrez et al. (25) demonstrated a significant inverse relationship between gluconeogenesis from lactate and pyruvate and the glucose concentration of the medium (with media glucose concentrations ranging from 2.5 to 30 mmol/l). Similarly, Ruderman & Herrera (5) observed a ~20% decrease in gluconeogenesis from alanine in perfused livers from overnight-fastened rats when the perfusate glucose was increased from 8.3 to 16.7 mmol/l. On the other hand, Exton & Park (2) failed to demonstrate any difference in the rate of gluconeogenesis from lactate in livers from 18–22 h fasted rats (which would have been virtually free of glycogen) when they were perfused with 12 vs 19 mmol/l glucose. Similarly, Davidson (12) found that isolated hepatocytes from normal rats incubated with 10 mmol/l pyruvate exhibited no suppression of gluconeogenesis when the glucose concentration in the
Mechanisms of autoregulation in response to hyperglycemia

The key molecular and enzymatic changes associated with autoregulation are only partially elucidated. In vivo data obtained from hyperglycemic rats (20) and humans (22) with basal insulin and glucagon concentrations indicate that a decrease in the activity of hepatic phosphorylase, or a decrease in phosphorylase activity accompanied by an increase in glycogen synthase activity, may explain the decrease in the rate of net glycogenolysis. Rossetti et al. (20) found that the increase in glucose cycling in the hyperglycemic animals was proportional to the increase in the plasma glucose concentration, suggesting that substrate availability was the primary stimulus for the increase in glucose cycling. Alternatively, changes in G-6-Pase could explain the enhancement in glucose cycling in response to hyperglycemia. Incubation of primary hepatocytes with glucose was observed to increase G-6-Pase mRNA 20-fold by 48 h, with maximal stimulation obtained with glucose concentrations as low as 11 mmol/l (26).

Insulin’s importance in the autoregulatory response to hyperglycemia probably results from its effect on the maintenance of glucokinase and glycogen synthase activity within the liver (12, 27). The hepatic glucose transporters GLUT-1 and GLUT-2 are membrane bound, and insulin is not required for their translocation (28). GLUT-1 has a low $K_m$ for glucose ($\sim 5$ mmol/l), while GLUT-2 has a high $K_m$ ($\sim 15$ mmol/l). Because of GLUT-2’s high $K_m$ for glucose, the blood glucose concentration is the primary determinant of glucose transport via GLUT-2 (28). Phosphorylation of glucose in the liver is primarily performed by glucokinase, which undergoes transcriptional regulation by a glucose-independent action of insulin (27). Some genes related to hepatic carbohydrate metabolism (most notably pyruvate kinase) contain glucose response elements and are activated by glucose in an insulin-independent manner, but glucose must be phosphorylated prior to the activation of gene transcription (29). Similarly, the most important effectors of glycogen synthase is glucose-6-phosphate (30). Thus glucose can stimulate its own intrahepatic metabolism, but even these ‘insulin-independent’ processes require insulin for the critical phosphorylation step. Glucokinase and glycogen synthase activities have been observed to be markedly reduced in chronic insulin deficiency (20, 27, 31). Diminished glucokinase and glycogen synthase activities, coupled with impaired phosphorylase activity, were found to contribute to enhancement of the glycogenolytic rate and maintenance of an elevated rate of basal hepatic glucose production in rats made chronically hyperglycemic and hypoinsulinemic by partial pancreatectomy (20).

In summary, in vivo evidence indicates that under usual circumstances (i.e. when hepatic glycogen stores are present) hyperglycemia inhibits hepatic glucose production primarily through a decrease in the glycogenolytic rate and an increase in glucose cycling (20–22, 47). When glycogen reserves are largely depleted, and the individual is relying more heavily upon gluconeogenesis to maintain hepatic glucose output, autoregulation may impact on the rate of gluconeogenesis (7). Evidence appears to support a multifactorial basis for autoregulation. Figure 2 illustrates some of the steps in hepatic glucose metabolism which are likely to be involved in this process.

Figure 2 Simplified diagram of relevant steps in hepatic carbohydrate metabolism, with likely sites for autoregulatory actions marked with asterisks. Either an increase in the substrate (glucose) supply or G-6-Pase activity could promote glucose cycling. Glucose-6-phosphate is the most potent enhancer of glycogen synthase activity (as shown by the dotted line), and the balance between the activities of glycogen synthase and phosphorylase determine whether glycogen synthesis or glycogenolysis is the dominant process.
**Autoregulation in response to hypoglycemia**

Ideally examination of the autoregulatory phenomenon would occur in the absence of pancreatic hormones or in the presence of only basal hormone concentrations. However, it is virtually impossible to induce hypoglycemia under euiinsulinemic conditions without using pharmacologic agents which would alter hepatic glucose production and thus interfere with assessment of the autoregulatory response. Therefore most in vivo investigations of autoregulation during hypoglycemia have been carried out in the presence of insulin-induced hypoglycemia.

In one of the first investigations in vivo, Saccá et al. (32) administered a continuous 3 h infusion of insulin to conscious overnight-fasted dogs. This resulted in a 3-fold increase in plasma insulin concentrations and a slow fall in plasma glucose, stabilizing at ~2.2 mmol/l. After 10 min of insulin infusion, EndoRₐ had fallen by 50%, from 20–100 min; however, EndoRₐ rose steadily. Within 30 min after the insulin infusion began (and at every time thereafter), EndoRₐ was significantly higher than at 10 min, and it had reached pre-infusion levels by 50 min. The reversal of the insulin inhibition of EndoRₐ began 20–50 min prior to measurable changes in counterregulatory hormone secretion (32). Thus the decline in blood glucose appeared to initiate changes in glucose-regulation by mechanisms other than increases in concentrations of counterregulatory hormones. There have been major improvements in tracer methodology since the publication of the work of Saccá et al. (32), which call into question the more quantitative aspects of the study. Nevertheless, their findings suggested that autoregulation contributes to the response to hypoglycemia in vivo and this stimulated further investigations.

In another series of experiments in the conscious dog, Frizzell et al. (33) examined three groups of animals receiving an insulin infusion which raised circulating insulin concentrations 20-fold basal. One group was allowed to develop hypoglycemia (to permit the investigators to quantify the counterregulatory response to the resulting glycemic level, ~2.2 mmol/l), one group received a glucose infusion to maintain euglycemia (and prevent the rise in counterregulatory hormones), and one group received a glucose infusion to maintain euglycemia plus infusions of glucagon, epinephrine, norepinephrine, and cortisol to mimic the counterregulatory hormone profile observed in the hypoglycemic group. In contrast to the euglycemic group without hormone replacement, the euglycemic group with counterregulatory hormone replacement exhibited an increase in EndoRₐ during the infusion period, but the increase was only 50% of that apparent in the hypoglycemic group (33). Thus, the response to hypoglycemia appeared to involve some factor(s) in addition to counterregulatory hormone secretion. The possibilities included a change in autonomic neural activity, the presence of hepatic autoregulation, or a change in hepatic sensitivity to the counterregulatory hormones in the presence of hypoglycemia. This study led to further work to discriminate between these three variables.

Evidence indicates that autoregulation plays a more significant role in the response to severe hypoglycemia than to moderate hypoglycemia (34, 35). Hansen et al. (36) studied human volunteers receiving infusions of: (i) somatostatin (to suppress glucagon and growth hormone secretion), insulin (~2-fold basal), and glucose to maintain euglycemia, or (ii) somatostatin, insulin, glucose, and pharmacologic blockers of epinephrine and norepinephrine action. When glucose infusion was decreased to allow the plasma glucose to fall to 3.6 mmol/l (a moderate hypoglycemic stimulus), glucose production increased 7.2 μmol/kg per min in the group receiving adrenergic blockade but did not change in the blockade group: when glucose was then infused to bring plasma glucose back to basal, glucose production decreased 8.3 μmol/kg per min (thus reversing all of the increase observed in response to hypoglycemia) and 2.8 μmol/kg per min in the nonblockade and the blockade groups respectively. The investigators concluded that counterregulatory hormones were responsible for almost all of the increase in glucose production observed, with autoregulation accounting for a maximum of 0–30% of the change in glucose production (36).

Bolli et al. (34) used pharmacologic agents to inhibit the secretion of glucagon, growth hormone, and cortisol and to block the actions of epinephrine and norepinephrine during insulin-induced hypoglycemia. They replaced glucagon and growth hormone at basal levels, and infused insulin to induce moderate (2.8 mmol/l) or more severe (1.7 mmol/l) hypoglycemia in human subjects. In the group with moderate hypoglycemia, EndoRₐ was rapidly suppressed ~70% and did not rise throughout the period of hyperinsulinemia. Glucose production was similarly suppressed when euglycemia was maintained by glucose infusion during the period of hyperinsulinemia (again in the presence of the pharmacologic blockers). In contrast, after an initial suppression of glucose production in the severely hypoglycemic group, EndoRₐ rose so that it was 2-fold greater than during euglycemia or moderate hypoglycemia. The investigators concluded that autoregulation was a component of the response to severe hypoglycemia (and was responsible for ~2.8 μmol/kg per min of glucose production) but had little importance at plasma glucose levels ≥2.8 mmol/l (34).

The studies of Hansen et al. (36) and Bolli et al. (34) in human subjects were limited by the investigators’ inability to control counterregulatory hormones completely. In the studies of Hansen et al. (36), for example, cortisol and growth hormone concentrations increased 166–221 nmol/l and 1 μg/l respectively during hypoglycemia. Moreover, adrenergic blockade does not have the same metabolic effect as epinephrine deficiency.
resulting from adrenalectomy (37). Connolly et al. (38) therefore conducted studies to define more precisely the relationship between plasma glucose concentrations and glucose metabolism in the conscious dog. Adrenalectomized dogs (lacking cortisol and epinephrine) were infused with somatostatin, as well as a high dose of intraportal insulin, resulting in arterial insulin concentrations of ~2000 pmol/l. Glucose was infused peripherally as needed to achieve four different glycemic plateaus in each dog (5.9, 3.4, 2.5, and 1.7 mmol/l). There were no detectable circulating concentrations of glucagon, epinephrine, or cortisol. (Growth hormone could not be measured due to the lack of a sensitive assay for canine growth hormone.) The liver exhibited hepatic glucose output. Nevertheless, the work of Connolly et al. (38) conclusively demonstrated in vivo that nonhormonal mechanisms (neural and/or autoregulatory) stimulate net hepatic glucose output in response to insulin-induced hypoglycemia. In addition, comparison of the data of Connolly et al. (38) with those of Frizzell et al. (33) made it possible to quantify the impact of nonhormonal mechanisms on the response to a glycemic level of ~2.5 mmol/l (a glucose concentration common to both investigations). Nonhormonal mechanisms, possibly including autoregulation, could account for approximately one-quarter of the change in net hepatic glucose balance observed at 2.5 mmol/l glucose (38).

The brain bears the responsibility for directing most of the rise in counterregulatory hormones seen in response to hypoglycemia (40), but it also may affect hepatic glucose metabolism directly via neural connections. It has been demonstrated in several species that electrical stimulation of the splanchic or hepatic nerves results in hyperglycemia, in spite of adrenalectomy and pancreatectomy (41, 42). Stimulation of the ventromedial hypothalamus results in enhancement of hepatic glycogenolysis and gluconeogenesis (43, 44). To separate the possible effects of glucopenia at the level of the central nervous system from direct effects of glucopenia on the liver Connolly et al. (45) conducted further studies in the conscious dog model. The dogs underwent adrenalectomy 2 weeks prior to experimentation, as in the previous investigation (38). During the studies, dogs received somatostatin, along with intraportal insulin infusion to produce arterial concentrations of ~1500 pmol/l. Glucose was infused peripherally as needed to maintain the plasma glucose level at ~2 mmol/l. One group of dogs also received glucose infusions via both common carotid and vertebral arteries, to maintain euglycemia within the brain, while the second group was allowed to develop brain hypoglycemia. Both groups switched from net hepatic uptake of glucose during the control period (systemic euglycemic hyperinsulinemia) to net hepatic release of glucose during the hypoglycemic period, with no difference in response between groups (change in net hepatic glucose balance ~12 μmol/kg per min in both groups). Thus maintenance of cerebral euglycemia did not prevent the rise in hepatic glucose release caused by the low blood glucose, and consequently liver hypoglycemia must have stimulated net hepatic glucose release (45). The results of this study do not rule out a role for the nervous system in the response observed (i.e. communication by the liver to the brain concerning the hypoglycemia at the level of the liver, with a
subsequent response by the brain), but they do indicate that an increase in hepatic glucose production can occur in response to hypoglycemia sensed within the liver and in the absence of a change in counterregulatory hormone secretion. The results are all the more impressive in view of the fact that insulin concentrations at the liver were high and should have represented a maximal inhibitory signal to glucose production, yet the liver clearly responded to hypoglycemia.

In a further effort to separate the direct response of the liver from the neurally mediated response to hypoglycemia, the same group of investigators (C C Connolly & A D Cherrington, unpublished observations) conducted additional studies in six adrenalectomized dogs which had also undergone surgical denervation of the liver. These animals were studied in the same manner as the adrenalectomized dogs described above: somatostatin was infused, hyperinsulinemia was created, cerebral euglycemia was maintained, and glucose was infused peripherally as needed to maintain circulating glucose at \( \approx 2 \text{ mmol/l} \). In this case, the change in net hepatic glucose balance during the hypoglycemic period was \( 6 \text{ mmol/kg per min} \), about half of the change observed in the animals with intact hepatic nerves. Although these data cannot be interpreted in a strictly quantitative sense, it is clear that a portion of the liver’s nonhormonally mediated response to hypoglycemia cannot be attributed to direct neural control.

Taken together, the studies described above indicate that nonhormonal mechanisms may be responsible for 25–30% of the change in hepatic glucose production in response to severe hypoglycemia (\( \leq 2.8 \text{ mmol/l} \)). This implies that the nonhormonal contribution to glucose production during hypoglycemia is sufficient to meet approximately half of the brain’s obligatory glucose requirement (34). Thus, even though nonhormonal mechanisms are responsible for a limited portion of the total hepatic response to hypoglycemia under usual conditions, their contribution is nevertheless physiologically significant since it occurs when there is a critical need for glucose.

**Mechanisms involved in hypoglycemic autoregulation**

Autoregulation in response to hypoglycemia apparently can involve both gluconeogenesis and glycogenolysis. Ruderman & Herrera (5) observed a 35% increase (\( P < 0.005 \)) in gluconeogenesis from \([^{14}\text{C}]\)alanine in rat livers perfused with a medium devoid of glucose, as opposed to those perfused with 16.6 mmol/l glucose. Net glycogenolysis occurred in the livers perfused without glucose, while livers perfused with 8.3 or 16.6 mmol/l glucose exhibited net glycogen synthesis (both \( P < 0.001 \) vs livers perfused without glucose) (5). When glycogen stores are present, an increase in the rate of glycogenolysis may be the preferred autoregulatory response to hypoglycemia. Livers from fed rats responded to a perfusion without glucose by releasing glucose and lactate into the perfusate, and the loss of tissue glycogen could account for all of the carbon released as glucose and lactate (3).

Enhancement of the rate of gluconeogenesis becomes an important facet of the autoregulatory response when glycogen reserves are low. McCraw et al. (4) examined the response of isolated rat livers to perfusate glucose concentrations ranging from 0 to 16.6 mmol/l in the presence of 20 mmol/l lactate. When livers of normal rats fasted for 24 h (and thus depleted in glycogen) were perfused with medium containing 2.8 and 0 mmol/l glucose, they exhibited 50% and 300% increases respectively in the rate of net glucose production in comparison to the rate observed during perfusion with 5.5 mmol/l glucose. Perfused livers from 12 h fasted adrenalectomized rats (which have a block of gluconeogenesis from lactate) demonstrated net uptake of glucose at 5.5 and 2.8 mmol/l perfusate glucose concentrations, and released only 41% as much glucose as normal livers when the perfusate was devoid of glucose (4).

**Conclusion**

The phenomenon of autoregulation plays an important role in regulation of hepatic glucose metabolism. In the presence of physiologic hyperglycemia (<12 mmol/l) with basal insulin and glucagon concentrations, hepatic glucose production may fall by as much as 60–90%. Following a relatively brief fast (i.e. overnight in the dog and human), reduction in hepatic glycogenolysis and enhancement of glucose cycling are the primary mechanism by which the autoregulatory response occurs. After a more prolonged fast, when hepatic glycogen concentrations have been reduced to a stable minimum, reduction in the gluconeogenic rate becomes the predominant mechanism of the autoregulatory response. Although the rate of hepatic glucose production is greater in individuals with non-insulin-dependent diabetes (NIDDM) than in persons without NIDDM, it appears that hepatic autoregulation also occurs in NIDDM (46).

The autoregulatory response to insulin-induced hypoglycemia makes its most significant contribution in the presence of very low circulating glucose levels (\( \leq 2.8 \text{ mmol/l} \)). Autoregulation is capable of significant stimulation of hepatic glucose production in the presence of severe hypoglycemia, providing as much as 3 \( \mu\)mol/kg per min of glucose, with both glycogenolysis and gluconeogenesis potentially contributing to the autoregulatory response. Although in vivo investigations have utilized insulin-induced hypoglycemia to examine the role of hepatic autoregulation, the in vitro data suggest that an autoregulatory response to hypoglycemia does not require insulin. The endocrine system is a dominant force in the response of the liver to hyperglycemia and hypoglycemia, but autoregulation
provides an important adjunctive mechanism which may become important in the event of severe derangement of circulating glucose levels or impairment of neuroendocrine function.

References

17. Shimazu T & Amakawa A. Regulation of glycogen metabolism in liver by the autonomic nervous system, II. Neural control of glycogenolytic enzymes. *Biochimica et Biophysica Acta* 1968 165 335–348.
38. Connolly CC, Adkins-Marshall BA, Neal DW, Pugh W, Jaspan JB &


42 Edwards AV & Silver M. Comparison of the hyperglycaemic and glycogenolytic responses to catecholamines with those to stimulation of the hepatic sympathetic innervation in the dog. *Journal of Physiology* 1972 223 571–593.


45 Connolly CC, Myers SR, Neal DW, Hastings JR & Cherrington AD. In the absence of counterregulatory hormones, the increase in hepatic glucose production during insulin-induced hypoglycemia in the dog is initiated in the liver rather than the brain. *Diabetes* 1996 45 1805–1813.


Received 13 October 1997
Accepted 2 December 1997